This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Curcumin Bioavailability in Glioblastoma Patients

This study has been completed.
Information provided by (Responsible Party):
Stephan Dützmann, Johann Wolfgang Goethe University Hospitals Identifier:
First received: October 20, 2012
Last updated: June 1, 2013
Last verified: June 2013
Measuring the bioavailability of orally administered curcumin in the tumors of glioblastoma patients.

Condition Phase
Patient Harboring Glioblastoma That Will Undergo Surgery Early Phase 1

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement of Intratumoral Concentration of the Nontoxic Natural Compound Curcumin in Glioblastoma Patients

Resource links provided by NLM:

Further study details as provided by Stephan Dützmann, Johann Wolfgang Goethe University Hospitals:

Primary Outcome Measures:
  • Concentration of Curcumin in Glioblastoma [ Time Frame: At Tumor resection ]
    At the time of surgery

Biospecimen Retention:   Samples Without DNA
Tumor tissue

Estimated Enrollment: 15
Study Start Date: October 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients harboring Glioblastoma

Inclusion Criteria:

  • Patients harboring Glioblastoma
  • Patient will undergo surgery

Exclusion Criteria:

  • BMI > 30
  • Liver and Kidney Function so compromised that medication is prescribed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01712542

Department of Neurosurgery, Johann Wolfgang Goethe-University
Frankfurt, Hessen, Germany, 60528
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospital
Principal Investigator: Stephan Duetzmann Goethe University
  More Information

Additional Information:
Responsible Party: Stephan Dützmann, M.D., Johann Wolfgang Goethe University Hospitals Identifier: NCT01712542     History of Changes
Other Study ID Numbers: JohannWGUH_Curcumin-01
Study First Received: October 20, 2012
Last Updated: June 1, 2013

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017